

RI

08-31-2001

COVER SHEET



To the Honorable Commissioner

101830151

attached original documents or copy thereof.

1. Name of conveying party(ies)  
Alkermes Controlled Therapeutics, Inc.

09/27/01

2. Name and address of receiving party(ies)  
1. Alkermes Controlled Therapeutics, Inc.; and  
Name: 2. Genentech

Internal Address:

RECEIVED  
AUG 27 2001

Additional name(s) of conveying party(ies) attached? [ ] Yes [X] No

3. Nature of conveyance:

- Assignment  Merger
- Security Agreement  Change of Name

Other **ASSIGNMENT OF AN UNDIVIDED JOINT INTEREST**

Street Address: 1. 64 Sidney Street  
2. F DNA Way

City: 1. Cambridge State: 1. MA ZIP: 1. 02139  
2. South San Francisco 2. CA 2. 94080

Execution Date: August 16, 2001

Additional name(s) & address(es) attached? [ ] Yes [X] No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)  
09/260,362

B. Patent No.(s)

Additional numbers attached? [ ] Yes [X] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Carolyn S. Elmore

Internal Address:

Hamilton, Brook, Smith & Reynolds, P.C.

Street Address: Two Militia Drive

City: Lexington State: MA ZIP: 02421-4799

6. Total number of applications and patents involved: [ 01 ]

7. Total Fee (37 C.F.R. 3.41)..... \$ 40.00

- Enclosed
- Authorized to charge any deficiencies or credit any overpayment to deposit account
- Authorized to be charged to deposit account

8. Deposit account number:

08-0380

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Susan M. Abelleira

Name of Person Signing

*Susan M. Abelleira*  
Signature

*August 24, 2001*  
Date

08/31/2001 DBYRME

00000002 09260362

Total number of pages including cover sheet, attachments, and document: [02]

01 FC:581

ASSIGNMENT

Whereas, by virtue of an Assignment recorded in the United States Patent and Trademark Office on Reel 9869, Frames 723 to 725, Alkermes Controlled Therapeutics, Inc, of 64 Sidney Street, Cambridge, Massachusetts 02139 is the owner of United States Patent Application Serial No. 09/260,362, entitled A Method For Purifying Human Growth Hormone, filed March 1, 1999.


Whereas, Genentech, Inc., a Delaware corporation, of 1 DNA Way, South San Francisco, California 94080 is desirous of acquiring from Alkermes Controlled Therapeutics, Inc. an undivided right, title and interest in, to and under the aforesaid Patent Application and the invention therein described and claimed in accordance with certain agreements duly entered into with us.

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, Alkermes Controlled Therapeutics, Inc. hereby sells, transfers and conveys an undivided right, title and interest in and throughout the United States of America, its territories and all foreign countries, in, to and under said invention as described and claimed in said application, together with an undivided right, title and interest in, to and under said application and such Letters Patent as may issue thereon to Genentech, Inc.; said invention, application and Letters Patent to be held and enjoyed by Alkermes Controlled Therapeutics, Inc. and Genentech, Inc. for their own use and behalf and for its successors, assigns and legal representatives consistent with said agreements, to the full end of the term for which said Letters Patent may be granted as the same would have been held by Alkermes Controlled Therapeutics, Inc. had this assignment and sale not been made; Alkermes Controlled Therapeutics, Inc. hereby conveys an undivided interest of all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent.

AND, Alkermes Controlled Therapeutics, Inc. does hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon jointly to Alkermes Controlled Therapeutics, Inc. and Genentech, Inc. their successors, assigns, and legal representatives.

IN TESTIMONY WHEREOF, ASSIGNOR has caused these presents to be signed by its duly authorized officer below named effective as of the date written below.

Alkermes Controlled Therapeutics, Inc.

By   
James M. Frates

Title Vice President, CFO

Date 16 - Aug - 01

:ODM A\MH ODM A\iManage:248040:1